Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Mucosis Announces a Strategic Partnership with Changchun BCHT Biotechnology

Published: Wednesday, April 16, 2014
Last Updated: Wednesday, April 16, 2014
Bookmark and Share
Company raises EUR 5 million in a new financing round.

Mucosis B.V. has announced that it has entered into a long-term collaboration and license agreement with China-based Changchun BCHT Biotechnology Co (BCHT) and raised EUR 5 million, in a new financing round.

Under the agreement with BCHT, Mucosis will receive an equity investment along with customary payments including royalties in return for a license to its SynGEM® prefusion F vaccine candidate for prevention of RSV and the Mimopath® platform for other disease targets within the People’s Republic of China on an exclusive basis and non-exclusively in certain other Asian countries. Further details of the agreement were not disclosed.

Changchun BCHT Biotechnology Co. was established in 2004 and is a 600-person biopharmaceutical enterprise engaging in research, development, production and marketing of vaccines, biologics and peptide drugs.

BCHT has a well-established innovative organization led by talented researchers and supported by facilities. The management team consists of members with broad international background along with extensive experience in China’s biopharmaceutical industry.

"We are pleased with BCHT joining a group of investors who share our confidence in the potential of our Mimopath® technology and the proprietary SynGEM® prefusion F RSV vaccine candidate. We believe that our Mimopath® platform combined with BCHT's expertise in vaccine development creates a substantial opportunity in China and other parts of Asia to develop differentiated and medically relevant vaccines", said Thomas Johnston, CEO of Mucosis.

Johnston continued, "We see this partnership as a further validation of our clinical-stage platform and its potential to combat infectious diseases. Lastly, we are grateful to Link China Pharma Solutions of Cambridge, UK for their invaluable assistance in brokering this deal."

“We are delighted to form this strategic partnership with Mucosis BV to advance the RSV SynGEM® vaccine program and develop other vaccine candidates based on the validated Mimopath® platform technology. I believe this business relationship between our two companies will strengthen our pipeline of new vaccine products.” said Dr Kong, President of Changchun BCHT Biotechnology Co.

In addition to BCHT, the financing round was supported by Mucosis’s current investors, which include BioGeneration Ventures, MedSciences Capital, NV NOM (Investment and Development Agency for the Northern Netherlands), and Utrecht Holdings.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Mucosis Secures €3.7M from Wellcome Trust
Funding will enable new intranasal vaccine SynGEM® to be tested in phase I and IIa human clinical trials.
Thursday, January 21, 2016
Mucosis Receives Financial Support from the Dutch Government
Company receives an innovation credit line of up to €5 million for its SynGEM® program.
Friday, May 23, 2014
ExpreS2ion, Mucosis, and University of Copenhagen Receive Eurostars Grant
Eurostars™ grant for the pre-clinical development of an innovative placental malaria vaccine.
Thursday, September 27, 2012
Mucosis Appoints Thomas Johnston to CEO
Mr. Johnston joined Mucosis as Chief Business Officer in May 2011, and succeeds Govert Schouten who is leaving the Company to found an internet start-up.
Monday, September 17, 2012
Mucosis Announces Positive Proof-Of-Concept Data for Mimopath® Platform in Humans
Mimopath®-based vaccines are able to produce balanced immune responses in both circulating blood and the respiratory tract.
Monday, May 14, 2012
Mucosis Announces Publication of Preclinical Data of Novel Influenza Vaccines
Mucosally administered Mimopath-based influenza vaccine protects against both homologous and heterologous challenge.
Thursday, May 03, 2012
Mucosis Announces New Scientific Advisory Board
Professors Jiri Mestecky, Willem van Eden and Peter J. Openshaw appointed to Scientific Advisory Board.
Friday, November 18, 2011
Mucosis Appoints Thomas Johnston as Chief Business Officer
Thomas Johnston will have global responsibility for the licensing and marketing of Mucosis’s technologies, negotiating corporate partnerships and other strategic alliances.
Monday, June 06, 2011
Mucosis Appoints Thomas Johnston as Chief Business Officer
Thomas have global responsibility for the licensing and marketing of Mucosis’s technologies, negotiating corporate partnerships and other strategic alliances.
Wednesday, May 18, 2011
Scientific News
Shedding Light on HIV Vaccine Design
Broadly speaking - Mathematical modelling of host-pathogen coevolution sheds light on HIV vaccine design.
Progress In Vaccination Against Vespid Venom
Researchers at the Helmholtz Zentrum München and the Technical University Munich have presented a method which facilitates a personalised procedure for wasp allergy sufferers.
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
New Method of Cancer Immunotherapy
Stanford chemists have dicovered a new form of cancer immunotherapy using sugar presence manipulation.
Vortex Ring Freezing Applications
Accidental lab discovery could aid cell delivery and cell-free protein production.
Examining Immune Memory
Researchers investigate the 'storage/research for the future' functions of antibodies and understanding of B cells.
Expanding the Stable of Workhorse Yeasts
New genome sequences target the next generation of yeasts with improved biotechnology uses.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Blocking the Migration of Cancer Cells to Destroy Them
Scientists in Geneva developed an antibody able to fight off lymphomas.
Mutations Linked to Immunotherapy Resistance
Researchers uncover mutations in tumors of three patients with advanced melanoma that allowed the tumors to become resistant to the immune checkpoint inhibitor pembrolizumab (Keytruda®).
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!